OPTIMISATION OF MOLECULAR ASSAYS FOR CLINICAL TRIAL OF GL67A/PDNA DELIVERY TO NOSE AND LUNG OF CF PATIENTS
Main Authors: | Sumner-Jones, S, McCormick, D, Coles, R, Pringle, I, McLachlan, G, Collie, D, Vrettou, C, Davies, J, Alton, E, Gill, DR, Hyde, S |
---|---|
Format: | Journal article |
Published: |
2009
|
Similar Items
-
3-STEP TAQMAN RT-PCR: ULTIMATE MESSENGER RNA DETECTION SENSITIVITY FOR CF GENE THERAPY CLINICAL TRIALS
by: McCormick, D, et al.
Published: (2009) -
Enhanced lung gene expression after aerosol delivery of concentrated pDNA/PEI complexes.
by: Davies, L, et al.
Published: (2008) -
EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CF: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY"
by: Davies, J, et al.
Published: (2009) -
REPEAT ADMINISTRATION OF GL67A/PGM169 IS FEASIBLE, SAFE, AND PRODUCES ENDOGENOUS LEVELS OF CFTR EXPRESSION AFTER 12 DOSES
by: Alton, E, et al.
Published: (2012) -
Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung
by: Alton, E, et al.
Published: (2012)